Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack

Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack

Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology’s 68thAnnual Scientific Session.

The trial, called TREAT, is the first large, international trial to assess ticagrelor’s safety and efficacy in patients taking fibrinolytic therapy, or “clot busters,” a class of drugs that break up the blood clots that cause heart attacks. Clot busters are used to treat heart attacks when it is not feasible to perform percutaneous coronary intervention (PCI), a procedure to open blocked arteries that is the gold standard for treating ST-elevation myocardial infarction (STEMI), the most severe type of heart attack.

In 2018, researchers reported the trial met its primary endpoint (major bleeding at 30 days) showing comparable safety between ticagrelor and clopidogrel. The current pre-specified analysis of efficacy and safety at 12 months suggests ticagrelor and clopidogrel have comparable efficacy and offers further confirmation that ticagrelor is safe to use in this patient population, researchers said.

Ticagrelor reduces clotting by preventing platelets from aggregating. It takes effect more quickly than clopidogrel. A previous study, called PLATO, found ticagrelor was superior to clopidogrel at preventing adverse cardiac events in patients with acute coronary syndromes—a group of conditions that includes heart attacks and unstable angina—who were not given clot busters. TREAT was designed to determine whether these benefits extend to patients given clot busters after STEMI.

“In spite of the fact that ticagrelor is more potent than clopidogrel, we found that it is safe to use ticagrelor in this population,” said Otavio Berwanger, MD, PhD, Chair of the Steering Committee and the study’s lead author. “In terms of efficacy, it is appropriate to interpret it statistically as a neutral trial, though it should be looked at in the broader context along with PLATO.”

The use of clot busters is most common where PCI is not available 24 hours a day, which includes most lower- and middle-income countries as well as some higher-income countries. The trial, conducted in 10 countries on five continents, included a mix of higher-income and lower-income countries and thus has worldwide relevance, researchers said.

The trial enrolled 3,800 patients treated for STEMI at more than 180 centers. All patients had received fibrinolytic therapy within 24 hours of their heart attack. Half of the participants were randomly assigned to take ticagrelor and half took clopidogrel. Patients were given an initial loading dose of their assigned drug and then continued taking the drug for 12 months.

At 12 months, researchers assessed rates of the key endpoint for the 12-month analysis, a composite of death from vascular causes, heart attack, stroke, severe recurrent ischemia, transient ischemic attack or another arterial thrombotic event. Eight percent of patients taking ticagrelor and 9.1 percent of those taking clopidogrel suffered these events, a difference that was not statistically significant.

Researchers noted that the trial was much smaller than PLATO, which had more than 18,000 participants, and had a lower than expected number of adverse events, limiting its statistical power. The risk reductions of ticagrelor as compared with the clopidogrel groups were identical in both studies; however, the gap was considered statistically significant in PLATO due to that trial’s larger size. When the researchers analyzed pooled data combining PLATO and TREAT, they found ticagrelor significantly improved outcomes compared to clopidogrel.

“The TREAT patients are exactly the population that was excluded from PLATO,” Berwanger said. “By combining both trials, we can say that ticagrelor is beneficial across the whole spectrum of patients with acute coronary syndromes, regardless of how they are managed in terms of fibrinolytic therapy.”

When TREAT data were analyzed alone, researchers found no significant difference in terms of the secondary composite endpoint that included death from vascular causes, heart attack or stroke, which occurred in 6.9 percent of those on ticagrelor and 7.3 percent of those on clopidogrel. They also found no significant differences in terms of the individual components of the composite endpoint or death from any cause.

Bleeding is the most common complication from blood thinners, which are used to help prevent heart attacks and strokes by reducing the body’s ability to clot blood. The TREAT researchers assessed rates of bleeding events using the criteria defined by the Thrombolysis in Myocardial Infarction (TIMI) score, as well as the Bleeding Academic Research Consortium (BARC) categories and the definition used in PLATO. Rates of the most important types of bleeding such as major bleeding and major and minor bleeding combined were low (between 1 and 2 percent) and not significantly different between the two groups, suggesting the safety of ticagrelor. However, rates of minor, non-clinically relevant bleeding (such as from a nosebleed or minor cut) were significantly higher in the ticagrelor group, with 5.9 percent reporting such bleeds compared with 2.9 percent among those taking clopidogrel. This difference was expected and in line with previous studies, Berwanger said.

Source:

https://www.acc.org/about-acc/press-releases/2019/03/18/09/20/ticagrelor-is-as-safe-and-effective-as-clopidogrel-after-heart-attack

About author

Related Articles